X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1795) 1795
male (1382) 1382
aged (1373) 1373
female (1349) 1349
middle aged (1321) 1321
tegafur - administration & dosage (1308) 1308
drug combinations (1193) 1193
antineoplastic combined chemotherapy protocols - therapeutic use (1040) 1040
tegafur - adverse effects (973) 973
adult (908) 908
oncology (902) 902
oxonic acid - administration & dosage (806) 806
antineoplastic combined chemotherapy protocols - adverse effects (803) 803
index medicus (687) 687
chemotherapy (661) 661
oxonic acid - adverse effects (622) 622
stomach neoplasms - drug therapy (568) 568
tegafur - therapeutic use (560) 560
s-1 (552) 552
treatment outcome (530) 530
cancer (483) 483
drug administration schedule (444) 444
5-fluorouracil (428) 428
oxonic acid - therapeutic use (416) 416
administration, oral (386) 386
aged, 80 and over (362) 362
uracil - administration & dosage (357) 357
cisplatin - administration & dosage (344) 344
fluorouracil (339) 339
stomach neoplasms - pathology (327) 327
antimetabolites, antineoplastic - adverse effects (318) 318
neoplasm staging (317) 317
antineoplastic combined chemotherapy protocols - administration & dosage (314) 314
cisplatin (286) 286
disease-free survival (286) 286
antimetabolites, antineoplastic - administration & dosage (279) 279
survival rate (272) 272
antimetabolites, antineoplastic - therapeutic use (263) 263
pharmacology & pharmacy (257) 257
trial (252) 252
adenocarcinoma - drug therapy (251) 251
medicine & public health (249) 249
carcinoma (228) 228
care and treatment (219) 219
chemotherapy, adjuvant (217) 217
gastric cancer (206) 206
leucovorin - administration & dosage (206) 206
uracil - adverse effects (204) 204
colorectal neoplasms - drug therapy (201) 201
research (200) 200
fluorouracil - administration & dosage (192) 192
therapy (191) 191
tegafur (184) 184
cancer research (183) 183
leucovorin (179) 179
deoxycytidine - analogs & derivatives (178) 178
capecitabine (176) 176
combined modality therapy (175) 175
retrospective studies (171) 171
stomach neoplasms - surgery (171) 171
uft (168) 168
clinical trials (165) 165
cisplatin - adverse effects (164) 164
stomach cancer (164) 164
oxaliplatin (162) 162
camptothecin - analogs & derivatives (161) 161
surgery (161) 161
neoplasm metastasis (160) 160
colorectal cancer (158) 158
dose-response relationship, drug (158) 158
lung neoplasms - drug therapy (158) 158
stomach neoplasms - mortality (153) 153
pharmacology/toxicology (148) 148
metastasis (146) 146
survival analysis (146) 146
pyridines - administration & dosage (145) 145
adjuvant chemotherapy (141) 141
camptothecin - administration & dosage (141) 141
antineoplastic agents (140) 140
antimitotic agents (136) 136
survival (136) 136
radiotherapy (133) 133
kaplan-meier estimate (130) 130
oncology, experimental (130) 130
irinotecan (129) 129
prospective studies (127) 127
follow-up studies (125) 125
fluorouracil - adverse effects (122) 122
lymphatic metastasis (122) 122
organoplatinum compounds - administration & dosage (122) 122
time factors (122) 122
colorectal neoplasms - pathology (120) 120
docetaxel (118) 118
deoxycytidine - administration & dosage (117) 117
combination (114) 114
drug therapy, combination (114) 114
gastrectomy (114) 114
liver neoplasms - secondary (114) 114
prognosis (114) 114
gemcitabine (112) 112
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1324) 1324
Japanese (523) 523
Chinese (11) 11
Spanish (11) 11
Russian (7) 7
German (6) 6
French (3) 3
Dutch (2) 2
Hungarian (1) 1
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 01/2015, Volume 26, Issue 1, pp. 141 - 148
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 3, pp. 215 - 221
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, pp. CD011746 - CD011746
Background Biliary tract cancers are a group of rare heterogeneous malignant tumours. They include intrahepatic and extrahepatic cholangiocar-cinomas,... 
MEDICINE, GENERAL & INTERNAL | INTRAHEPATIC CHOLANGIOCARCINOMA | RISK-FACTORS | RANDOMIZED PHASE-II | DESIGN CHARACTERISTICS | FINDINGS TABLES | EMPIRICAL-EVIDENCE | GALLBLADDER CANCER | POOLED ANALYSIS | SINGLE-AGENT GEMCITABINE | TRIAL SEQUENTIAL-ANALYSIS | Capecitabine - administration & dosage | Gallbladder Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biliary Tract Neoplasms - mortality | Ampulla of Vater | Cisplatin - administration & dosage | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Oxaliplatin | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Mitomycin - adverse effects | Piperidines - administration & dosage | Tegafur - adverse effects | Cholangiocarcinoma - mortality | Oxonic Acid - administration & dosage | Oxonic Acid - adverse effects | Randomized Controlled Trials as Topic | Antimetabolites, Antineoplastic - therapeutic use | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Capecitabine - adverse effects | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Cisplatin - adverse effects | Tegafur - administration & dosage | Gallbladder Neoplasms - pathology | Mitomycin - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 11, pp. 1063 - 1069
Summary Background The best chemotherapy regimen for metastatic gastric cancer is uncertain, but promising findings have been reported with irinotecan plus... 
Hematology, Oncology and Palliative Medicine | SUPPORTIVE CARE | 5-FLUOROURACIL | ONCOLOGY | HIGH-DOSE METHOTREXATE | DOXORUBICIN | ADVANCED ESOPHAGOGASTRIC CANCER | COOPERATIVE GROUP | EUROPEAN-ORGANIZATION | 1ST-LINE THERAPY | III TRIAL | CHEMOTHERAPY | Japan - epidemiology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - secondary | Cisplatin - administration & dosage | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - adverse effects | Time Factors | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Drug Administration Schedule | Risk Assessment | Administration, Oral | Tegafur - adverse effects | Tegafur - therapeutic use | Proportional Hazards Models | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Oxonic Acid - adverse effects | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Infusions, Intravenous | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Chemotherapy | Oncology, Experimental | Information services | Research | Metastasis | Stomach cancer | Information services industry | Cancer | Fluorouracil | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 20, pp. 2600 - 2606
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 919 - 927
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2011, Volume 68, Issue 1, pp. 157 - 164
Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety... 
Medicine & Public Health | Gemcitabine | Pancreatic cancer | Oncology | Cancer Research | Curcumin | Pharmacology/Toxicology | APOPTOSIS | ACTIVATION | CELL-PROLIFERATION | SUPPRESSION | I CLINICAL-TRIAL | 5-FLUOROURACIL | THERAPY | INHIBITION | ONCOLOGY | GENE-PRODUCTS | PHARMACOLOGY & PHARMACY | EXPRESSION | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - administration & dosage | Curcumin - administration & dosage | Pancreatic Neoplasms - drug therapy | Adenocarcinoma - physiopathology | Antineoplastic Agents - adverse effects | Deoxycytidine - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Pancreatic Neoplasms - mortality | Deoxycytidine - administration & dosage | Tegafur - adverse effects | Tegafur - therapeutic use | Curcumin - pharmacokinetics | Survival Rate | Curcumin - adverse effects | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Drug Synergism | Medication Adherence | Oxonic Acid - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents - blood | Aged | Pancreatic Neoplasms - physiopathology | Deoxycytidine - analogs & derivatives | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Care and treatment | Cancer patients | Chemotherapy | Gastrointestinal agents | Oncology, Experimental | Research | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 90 - 98
Journal Article